Home / Products / (R)-2-((4-Nitrophenethyl)amino)-1-phenylethan-1-ol Hydrochloride
CAS 521284-21-9 Mirabegron Impurity F Mirabegron Impurity F High Purity USP Grade EP Grade Reference Standard

(R)-2-((4-Nitrophenethyl)amino)-1-phenylethan-1-ol Hydrochloride

IUPAC: (1R)-2-[[2-(4-Nitrophenyl)ethyl]amino]-1-phenylethan-1-ol Hydrochloride View on PubChem
CAS NUMBER
521284-21-9
MOL. FORMULA
C16H19ClN2O3
MOL. WEIGHT
322.79 g/mol
Scientific Overview

This compound arises from reduction of the amide carbonyl in the upstream hydroxyacetamide precursor (Mirabegron EP Impurity G), converting the amide linkage to a secondary amine while retaining the nitro group. Subsequent catalytic transfer hydrogenation (ammonium formate, Pd/C) reduces the nitro group to an amine, yielding (R)-2-((4-aminophenethyl)amino)-1-phenylethan-1-ol --- the final intermediate before thiazole coupling completes mirabegron's structure. As a hydrochloride salt, this form offers improved crystallinity and handling stability for process chemistry and reference standard applications.

(R)-2-((4-Nitrophenethyl)amino)-1-phenylethan-1-ol hydrochloride, designated Mirabegron Impurity F, is a chiral secondary amine hydrochloride salt bearing a nitrophenyl substituent. It occupies a pivotal midpoint in the mirabegron synthetic pathway, positioned directly between the hydroxyamide precursor (EP Impurity G) and the diaminophenol intermediate that couples with the drug's thiazole fragment.

Full Technical Data
Chemical Name (R)-2-((4-Nitrophenethyl)amino)-1-phenylethanol Hydrochloride (Mirabegron Impurity F)
CAS Number 521284-21-9
IUPAC Name (1R)-2-[[2-(4-Nitrophenyl)ethyl]amino]-1-phenylethan-1-ol Hydrochloride
Molecular Formula C16H19ClN2O3
Molecular Weight 322.79 g/mol g/mol
Reaction Scheme
(R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide (Mirabegron EP Impurity G)
NA
NA
(R)-2-((4-Nitrophenethyl)amino)-1-phenylethanol Hydrochloride
NA
Commercial Applications

Mirabegron API Manufacturing

Central synthetic intermediate connecting the amide-reduction and nitro-reduction stages of mirabegron production.

Pharmacopeial Impurity Reference Standard

Designated Mirabegron Impurity F for quality control testing and impurity profiling.

Regulatory Submission Support

Used in ANDA/NDA filings requiring characterized process-related impurity reference materials.

Process Chemistry & Route Validation

Supports API manufacturing process development and analytical method validation.

Market Therapeutic Focus
MIRABEGRON IMPURITY F PHARMACEUTICAL MANUFACTURING UROLOGY / OVERACTIVE BLADDER THERAPEUTICS ANALYTICAL REFERENCE STANDARDS API PROCESS CHEMISTRY CRO/CDMO
Scientific Literature

Mirabegron: A Review of its Use in Overactive Bladder Syndrome

Authors: Cui, Y. et al.

Drugs

Synthesis and Structure-Activity Relationships of ß3-Adrenergic Receptor Agonists

Authors: Ohtake, Y. et al.

J. Med. Chem.

Process Development and Impurity Control for Mirabegron API Manufacturing

Authors: Various

Org. Process Res. Dev. (process chemistry reference)

Peer Queries & FAQs
Where does this compound sit in the mirabegron synthesis pathway?
It's the midpoint intermediate: formed by reducing the amide of Mirabegron EP Impurity G, and itself reduced (at the nitro group) to yield the final aminoalcohol intermediate before thiazole coupling.
Why is the hydrochloride salt form used?
The HCl salt improves crystallinity, stability, and ease of handling/purification compared to the free base, which is common practice for amine-containing pharmaceutical intermediates.
How does this differ from Mirabegron Impurity 6 (CAS 391901-45-4)?
This compound retains the nitro group (not yet reduced to an amine), representing one synthetic step earlier than the fully reduced diaminophenol intermediate.
What is the recommended storage condition?
Store in a tightly sealed container at 2--8°C, protected from light and moisture.

Need a Custom Derivative or Labeled Analog?

Our R&D centers specialize in the design and process development of complex heterocyclic and chiral molecules — mg to kg scale.